Long-term protection at 20-31 years after primary vaccination with plasma-derived hepatitis B vaccine in a Chinese rural community

Background: To assess the long-term protection conferred by plasma-derived hepatitis B vaccine at 20-31y after primary immunization during infancy in Chinese rural community. Method: Participants born between 1986 and 1996, who received a full course of primary vaccination with plasma-derived hepati...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2020-01, Vol.16 (1), p.16-20
Main Authors: Ma, Jing-Chen, Wu, Zhi-Wei, Zhou, Hai-Song, Gao, Zhao, Hao, Zhi-Yong, Jin, Fei, Zhang, Yan-Hong, Li, Min-Jie, Wang, Feng, Li, Qi, Bi, Sheng-Li, Zhao, Yu-Liang
Format: Article
Language:English
Subjects:
Adult
China
Cohort Studies
Female
Hepatitis B - epidemiology
Hepatitis B - prevention & control
Hepatitis B Antibodies - blood
Hepatitis B Surface Antigens - immunology
Hepatitis B Vaccines - administration & dosage
Hepatitis B virus
Humans
Immunologic Memory
long-term protection
Male
primary vaccination
Research Paper
Rural Population
Surveys and Questionnaires
Time Factors
vaccine
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: To assess the long-term protection conferred by plasma-derived hepatitis B vaccine at 20-31y after primary immunization during infancy in Chinese rural community. Method: Participants born between 1986 and 1996, who received a full course of primary vaccination with plasma-derived hepatitis B vaccine and had no experience with booster vaccination were enrolled. An epidemiological investigation was performed, and blood samples were collected to detect hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc). The positive rate of HBsAg, anti-HBs, and anti-HBc were calculated to evaluate the long-term protection of the plasma-derived hepatitis B vaccine. Results: A total of 949 participants were enrolled in the final analysis. Six subjects were detected to be HBsAg-positive, resulting in a HBsAg carrier rate of 0.63% (6/949). A total of 468 (52.41%) participants maintained a level of anti-HBs antibody ≥10 mIU/mL, with a GMC of 112.20 mIU/mL (95%CI: 97.72 ~ 128.82 mIU/mL). A significant downtrend was observed in the anti-HBs positive rate (P < .001). The average anti-HBc positive rate was 5.90% (56/949), increased with prolongation of immunization (P < .001). Conclusions: The plasma-derived hepatitis B vaccine maintained satisfactory protection at 20-31 y after primary immunization. These results indicate that a booster dose is not necessary. Further studies on the immune memory induced by the plasma-derived hepatitis B vaccine are needed.
ISSN:2164-5515
2164-554X
DOI:10.1080/21645515.2019.1646575